A5048413999- Prion Diseases and Protein Misfolding
- Alcoholism and Thiamine Deficiency
- Amyotrophic Lateral Sclerosis Research
- Neurological diseases and metabolism
- Alzheimer's disease research and treatments
- Parkinson's Disease Mechanisms and Treatments
- Neurogenetic and Muscular Disorders Research
- Cerebrospinal fluid and hydrocephalus
- Intracerebral and Subarachnoid Hemorrhage Research
- S100 Proteins and Annexins
- Dementia and Cognitive Impairment Research
- Neurological disorders and treatments
- Sleep and related disorders
- Spinal Dysraphism and Malformations
- Fetal and Pediatric Neurological Disorders
- Sleep and Wakefulness Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Botulinum Toxin and Related Neurological Disorders
- Neuroscience and Neuropharmacology Research
Istituto delle Scienze Neurologiche di Bologna
2018-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2024
University of Bologna
2022-2023
Agenzia Sanitaria e Sociale Regionale
2022
Regione Emilia-Romagna
2022
Ospedale Bellaria
2019-2020
Institute of Neurological Sciences
2018
Abstract Background Increasing evidence supports the use of plasma biomarkers neurodegeneration and neuroinflammation to screen diagnose patients with dementia. However, confirmatory studies are required demonstrate their usefulness in clinical setting. Methods We evaluated cerebrospinal fluid (CSF) samples from consecutive frontotemporal dementia (FTD) ( n = 59), progressive supranuclear palsy (PSP) 31), corticobasal syndrome (CBS) 29), Lewy bodies (DLB) 49), Alzheimer disease (AD) 97),...
Abstract Background In neurodegenerative dementias (NDs) such as prion disease, Alzheimer’s disease (AD), and frontotemporal lobar degeneration (FTLD), protein misfolding leads to the tissue deposition of aggregates which, in turn, trigger neuroinflammation neurodegeneration. Cerebrospinal fluid (CSF) biomarkers have potential reflect different aspects these phenomena across distinct clinicopathological subtypes stages. Methods We investigated CSF glial markers, namely chitotriosidase 1...
Neurofilament light chain protein (NfL) is a surrogate biomarker of neurodegeneration that has never been systematically tested, either alone or in combination with other biomarkers, atypical/rapidly progressive neurodegenerative dementias (NDs). Using validated, commercially available enzyme-linked immunosorbent assay kits, we measured cerebrospinal fluid (CSF) NfL, total tau (t-tau), phosphorylated tau, and β-amyloid 42 subjects neuropathological clinical diagnosis prion disease (n = 141),...
Neurofilament light chain (NfL) and α-synuclein oligomeric seeds (α-syn-s) are promising biomarkers for patients with parkinsonism. We assessed their performance in discriminating Parkinson disease (PD) from atypical parkinsonisms (APDs) evaluated the association between NfL levels clinical measures of severity. measured cerebrospinal fluid (CSF) and/or plasma by immunoassays α-syn-s CSF real-time quaking-induced conversion (RT-QuIC) PD (n = 153), multiple system atrophy (MSA) 80),...
Background: Neurofilament light chain (NfL) is a validated biofluid marker of neuroaxonal damage with great potential for monitoring patients neurodegenerative diseases. We aimed to further validate the clinical utility plasma (p) vs. CSF (c) NfL distinguishing Amyotrophic Lateral Sclerosis (ALS) from ALS mimics. also assessed association biomarker values variables and survival established longitudinal changes pNfL during disease course. Methods: studied 231 prospectively enrolled suspected...
Phosphorylated-tau181 (p-tau181), a specific marker of Alzheimer's disease (AD) pathology, was found elevated in plasma but not cerebrospinal fluid (CSF) patients with amyotrophic lateral sclerosis (ALS). We expanded these findings larger patient cohort, exploring clinical/electrophysiological associations, prognostic value and longitudinal trajectories the biomarker.We obtained baseline samples from 148 ALS, 12 spinal muscular atrophy (SMA), 88 AD patients, 60 healthy controls. Baseline CSF...
Cerebrospinal fluid (CSF) neurofilament light chain protein (NfL) and Alzheimer's disease (AD) core biomarker levels have been evaluated in cohorts of patients with frontotemporal dementia spectrum (FTD), but the distribution values across different clinical syndromes underlying proteinopathies, relative diagnostic accuracy appear discordant among studies. We measured CSF NfL, total (t)-tau, phosphorylated (p)-tau, amyloid-β (Aβ)42 healthy controls (n = 38) subjects a clinical, genetic,...
Objective To compare the diagnostic accuracy and prognostic value of blood cerebrospinal fluid (CSF) tests across prion disease subtypes. Methods We used a single-molecule immunoassay to measure tau neurofilament light chain (NfL) protein levels in plasma assessed CSF total(t)-tau, NfL 14-3-3 patients with (n=336), non-prion rapidly progressive dementias (n=106) non-neurodegenerative controls (n=37). then evaluated each marker for diagnosis their association survival, taking into account...
Abstract Objective Despite the critical importance of pathologically confirmed samples for biomarker validation, only a few studies have correlated CSF A β 42 values in vivo with postmortem Alzheimer's disease ( AD ) pathology, while none evaluated 42/A 40 ratio. We compared and ratio as biomarkers predicting neuropathological changes patients short interval between lumbar puncture death. Methods measured assessed pathology 211 subjects rapidly progressive dementia RPD definite diagnosis...
Background The introduction of the prion Real-Time Quaking-Induced Conversion assay (RT-QuIC) has led to a revision diagnostic criteria for sporadic Creutzfeldt-Jakob disease (sCJD). Validation studies are needed amended criteria, especially their value in clinical setting. Methods We studied 1250 patients with suspected CJD referred diagnosis two Italian reference centres between 2010 and 2020. Focusing on first assessment, we compared old that different combinations variables biomarker...
Cerebrospinal fluid (CSF) biomarkers have been extensively investigated in idiopathic normal pressure hydrocephalus (iNPH) with the aim of a better differential diagnosis, but pathophysiological mechanisms underlying CSF biomarker changes and relationship between levels clinic al variables are still matter debate. We evaluated amyloid-β (Aβ)42 Aβ40, total (t)-tau, phosphorylated (p)-tau, prion protein (t-PrP), neurofilament light chain (NfL) healthy controls (n = 50) subjects iNPH 71),...
The diagnostic and prognostic value of plasma glial fibrillary acidic protein (pl-GFAP) in sporadic Creutzfeldt-Jakob disease (sCJD) has never been assessed the clinical setting rapidly progressive dementia (RPD). Using commercially available immunoassays, we assayed levels GFAP, tau (pl-tau), neurofilament light chain (pl-NfL) CSF total (t-tau), 14-3-3, NfL, phospho-tau181 (p-tau), amyloid-beta isoforms 42 (Aβ
Abstract Objective SerpinA1 (alpha‐1 antitrypsin) is an acute inflammatory protein, which seems to play a role in neurodegeneration and neuroinflammation. In Alzheimer’s disease synucleinopathies, overexpressed the brain cerebrospinal fluid (CSF) showing abnormal patterns of its charge isoforms. To date, no comprehensive studies explored CSF isoforms Creutzfeldt–Jakob (CJD) frontotemporal lobar degeneration (FTLD). Methods Using capillary isoelectric focusing immunoassay, we analyzed control...
The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) patients with Creutzfeldt-Jakob disease (CJD) prognostic potential. However, no validation studies assessed these biomarkers' diagnostic value a large clinical setting cohort rapidly progressive dementia.In this retrospective study, using commercially available immunoassays, we measured SNAP-25, Ng, 14-3-3, total-tau (t-tau),...
Abstract Introduction Surrogate cerebrospinal fluid (CSF) biomarkers of neurodegeneration still have a central role in the first‐line screening patients with suspected Creutzfeldt‐Jakob disease (CJD). Recently, CSF α‐synuclein, marker synaptic damage, showed close to optimal performance distinguishing between CJD and other neurodegenerative dementias. Methods We evaluated diagnostic value α‐synuclein prion disease, non‐prion rapidly progressive dementias, non‐neurodegenerative controls....
Idiopathic normal pressure hydrocephalus (iNPH) is a clinico-radiological syndrome of elderly individuals likely sustained by different neurodegenerative changes as copathologies. Since iNPH potentially reversible condition, assessing pathologies in vitam through CSF biomarkers and their influence on clinical features surgical outcome represents crucial steps.We measured α-synuclein seeding activity related to Lewy body (LB) pathology the real-time quaking-induced conversion assay (RT-QuIC)...
Abstract Study Objectives To measure the levels of five neurodegenerative biomarkers in cerebrospinal fluid (CSF) patients with narcolepsy type 1 (NT1) variable disease duration. Methods Following a standardized protocol CSF collection and storage, we measured total- phosphorylated-tau, amyloid-beta 1–40 1–42, neurofilament light chain (NfL) proteins 30 nonneurological controls 36 subjects NT1, including 14 recent onset (i.e. ≤12 months, short duration group). Results all were similar NT1...
Recent studies reported increased plasma glial acidic fibrillary protein (GFAP) levels in amyotrophic lateral sclerosis (ALS) patients compared to controls. We expanded these findings a larger cohort, including 156 ALS and 48 controls, investigated the associations of GFAP with clinical variables other biofluid biomarkers. Plasma Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers were assessed by single molecule array Lumipulse platforms, respectively. In patients, was higher than...
Abstract Background . Increasing evidence support the clinical implementation of plasma biomarkers neurodegeneration and neuroinflammation for screening diagnosis patients with dementia. However, confirmatory studies are required to demonstrate their usefulness in real-world setting, which co-existence multiple pathologies dementia is common. Methods We evaluated cerebrospinal fluid (CSF) samples from consecutive frontotemporal (FTD) (n=59), progressive supranuclear palsy (PSP) (n=31),...
Abstract Background The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) patients with Creutzfeldt-Jakob disease (CJD) prognostic potential. However, no validation studies assessed these biomarkers' diagnostic value a large clinical setting cohort rapidly progressive dementia. Methods In this retrospective study, using commercially available immunoassays, we measured SNAP-25, Ng,...
Diagnostic value of CSF biomarkers in the comparison between subjects with ND and control subjects. Table S2. differential diagnosis prion disease, AD, FTLD. Figure S1. ROC analysis disease AD. atypical other atypical/rapidly progressive NDs. S3. (DOCX 1967 kb)